Epidemiologic data frompatients with type 2 DM treated with TZDs suggest that these ligands of PPARγ are protective against lung cancer butnot against colon or prostate cancer [50].With the impressive in vitro data and suggestive findings fromepidemiology, oncologists have proposed that PPARγ is an attractive target for cancertreatment. This evidence concerns the gene PPARG and Familial prostate cancer.